In this week’s video, Dr. Durie discusses the CANDOR trial, a randomized phase III clinical trial studying the three-drug combination therapy of Kyprolis®, Darzalex®, and dexamethasone. 

BOTTOM LINE:
The CANDOR trial is a randomized phase III clinical trial showing promising results for relapsed/refractory patients. Participants’ median remission length has yet to be determined.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org

Transcript:

This week’s “Ask Dr. Durie” comes from a patient who wants to know, “What is the CANDOR trial?”
 
Well, this is a trial that was recently in the news. The CANDOR trial was announced in a press release from the AMGEN corporation indicating that in this study, the combination of Kyprolis®, daratumumab, and dex gave results superior to the doublet of Kyprolis and dexamethasone. This was important because the length of the remission was superior with the three-drug verses the two-drug in this randomized phase III trial in patients with relapsed/refractory myeloma.
 
The amount of the difference was clearly significant at this point, the length of the remission, the average length of the remission has not yet been reached for the three-drug combination of Kyprolis, daratumumab, and dex. The length of the remission with the doublet, the PFS is fifteen point eight months.
 
In the big picture, what this means is that with the three-drug combo KDd, there is a thirty-seven percent reduction in the risk of relapse or death with that combo versus the doublet.
 
Additional important points about this are that this particular combination in the CANDOR trial showed benefits in patients with high-risk disease. And so, this is particularly important relative to daratumumab in, for example. The MAIA trial where there was not such strong benefit in patients with high-risk disease.
 
So, this is an important trial which supported a single-arm study that was completed and published just recently in the journal, Blood. And this particular trial, the Kyprolis was given once a week, which is quite encouraging for patients because this is a more convenient schedule.  
 
So, BOTTOM LINE, the CANDOR study, the CANDOR trial is an important new study indicating the benefit with the triplet of Kyprolis, daratumumab, and dex. And this is an important addition to our armamentarium for the relapse, refractory patient.

 

Previous Post
Can blood testing replace bone marrow testing for multiple myeloma?
Next Post
What is a BEAT

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.